MP CARDIOFLOW-B(02160): Shanghai Micro-Port MedBot and Shanghai Huiqing Orange Investment Management have entered into a leasing agreement.

MP CARDIOFLOW-B (02160) announced that on July 31, 2026 (after market close), its wholly-owned subsidiary, Shanghai MicroPort CardioFlow, entered into Lease Agreement I with the owner, Shanghai Huiqing Orange Investment Management Co., Ltd. According to this agreement, Shanghai MicroPort CardioFlow agrees to lease Property I from the owner for a period of five years, from August 1, 2026, to July 31, 2031 (inclusive of the first and last days). On July 31, 2026 (after market close), the company's wholly-owned subsidiary, Chuangling Cardiac Medical, entered into Lease Agreement II with the owner. According to this agreement, Chuangling Cardiac Medical agrees to lease Property II from the owner for a period of five years, from August 1, 2026, to July 31, 2031 (inclusive of the first and last days). Property I and Property II are parts of industrial facilities specifically constructed for the owner, located at 1661 Zhangdong Road, China (Shanghai) Pilot Free Trade Zone, and 2585 Zu Chongzhi Road, with building areas of approximately 9042.09 square meters and 4634.95 square meters, respectively. The properties were specifically built for the operations of the Group. After completion, the Group began leasing the properties and entered into related lease agreements in May 2021 for their production use, which expired before the effective date of the lease agreement (2021 Lease Agreement). For details, please refer to the company's announcements dated May 13, 2021, and June 11, 2021. The Group intends to continue using the properties for production purposes to support its expansion plans. The continued leasing of the properties is beneficial and crucial for the company's daily production activities, ensuring operational stability and supporting the Group's ongoing business development.